Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

BACKGROUND: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasa, BJ, Lalkota, Bhanu Prakash, Badarke, Girish, Hazarika, Diganta, Mohammad, Nasiruddin, Sapkota, Sulav, Khanderia, Mansi, Tousif, D, Rao, Raghavendra, Ram, Amritanshu, Patil, Shekar, Naik, Radheshyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055235/
https://www.ncbi.nlm.nih.gov/pubmed/30046259
http://dx.doi.org/10.1177/1179554918782475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055235/
https://www.ncbi.nlm.nih.gov/pubmed/30046259
http://dx.doi.org/10.1177/1179554918782475

Ejemplares similares